Clik here to view.
Lilly’s breast cancer drug combination succeeds key study
Eli Lilly and Co’s combination of its experimental breast cancer drug and another widely used treatment slowed disease progression in patients who relapsed or did not benefit enough when treated with...
View ArticleClik here to view.
Novartis heart failure drug sinks at Phase 3 trials
Novartis’ serelaxin was once thought to be the major hope for its cardiovascular pipeline – analysts projected it to become a blockbuster and Novartis thought it could shore up gaps in its portfolio...
View ArticleClik here to view.
Takeda clinches massive enrollment goal in phase 3 dengue study
Less than seven months after kicking off its largest vaccine trial to date, Takeda has finished enrolling 20,100 children for a mammoth phase 3 dengue study in eight endemic countries. Investigators...
View ArticleClik here to view.
Roche’s lung cancer drug beats Pfizer rival in study
Roche has announced that its drug Alecensa (alectinib) succeeded in meeting its primary endpoint in a Phase 3 trial assessing its efficacy as a first-line treatment of anaplastic lymphoma kinase...
View ArticleClik here to view.
Tolerability, Adherence to Alzheimer’s Drugs Assessed
Overall, the researchers found no variation in tolerability or adherence to the 3 medications based on gender, race, education or age. Findings from the first real-world study comparing patient...
View ArticleClik here to view.
Shire’s angioedema drug succeeds in late-stage study
Shire Plc said successful late-stage data on its long-acting drug for hereditary angioedema would form the basis of a U.S. marketing application for the treatment. U.S.-listed shares of company, which...
View ArticleClik here to view.
AstraZeneca phase IIIb/IV EXSCEL of Bydureon meets primary endpoint
AstraZeneca has announced top─line results from the phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial. The trial compared the effect of once─weekly Bydureon (exenatide...
View ArticleClik here to view.
Swiss biotech NLS Pharma’s ADHD drug succeeds in mid-stage study
Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a...
View ArticleClik here to view.
Immuno-oncology upset in bladder cancer
Roche and Genentech’s checkpoint inhibitor atezolizumab did not improve overall survival in a confirmatory phase III trial in patients with advanced bladder cancer. The FDA granted accelerated...
View ArticleClik here to view.
Novartis touts new T-cell therapy data in race for FDA approval
Novartis on Wednesday touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive...
View ArticleClik here to view.
Sanofi-Regeneron’s Praluent cuts cholesterol in Odyssey trials
France’s Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and...
View ArticleClik here to view.
Twee fase-3 onderzoeken met sotagliflozine bij type 1 diabetespatiënten...
Sotagliflozin (SOTA) is een orale remmer van zowel SGLT-1 als SGLT-2. Al eerder is aangetoond dat het een effectief en goed getolereerd middel is om de bloedglucose in type 1 en type 2...
View ArticleClik here to view.
Type 1 Diabetes Reversal May be Possible with TB Vaccine
Faustman’s team is preparing for a 5-year, 150-person Phase 2 trial to investigate the potential for repeat BCG vaccination to improve type 1 diabetes in adults with existing disease. According to data...
View ArticleClik here to view.
Boehringer Ingelheim presents phase III results demonstrating clinical...
Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and...
View ArticleClik here to view.
Breakthrough study could revolutionise MS treatment
The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from all quarters, given that it seems to show the repair of myelin damaged by...
View Article